Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266)

Overview

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. is a prominent entity in the pharmaceutical industry, deeply engaged in the research, development, production, and sales of medicines within the People's Republic of China. Originating in 2009, the company has established its operational base in Kunshan, showcasing a strong commitment to advancing healthcare through innovation. Suzhou Zelgen Biopharmaceuticals specializes in creating effective treatment solutions across a wide spectrum of diseases, including various types of cancer and autoimmune diseases, underlining its role as a critical player in improving patient care and outcomes.

Products and Services

Donafenib Tablets: Developed for the treatment of liver cancer, these tablets represent a significant advancement in therapeutic options for patients battling this challenging disease.

Recombinant Human Thrombin for Topical Use: This product plays a crucial role in managing bleeding during surgeries, offering a highly effective solution for this pervasive healthcare challenge.

Jacktinib Tablets: Targeting non-small cell lung cancer and small cell lung cancer, these tablets are at the forefront of lung cancer treatment, providing new hope for affected patients.

Recombinant Human Thyroid-Stimulating Hormone for Injection: Specifically designed for the management of thyroid cancer, this injectable hormone aids in both treatment and diagnostic procedures, enhancing patient care.

Obeticholic Acid Magnesium Tablets: These tablets are used in the treatment of hepatobiliary diseases, reflecting the company's dedication to addressing a range of liver and gallbladder disorders.

ZG19018 Tablets: As part of the company's oncology portfolio, these tablets are another innovative solution for the treatment of various cancers, demonstrating Suzhou Zelgen's ongoing commitment to combating this disease.

ZG005 Powder for Injection: Developed for managing colorectal cancer, this powder for injection signifies a vital tool in the fight against a leading cause of cancer-related death worldwide.

Alkotinib Capsules: Focused on addressing non-small cell lung cancer and neuroendocrine cancer, these capsules showcase the company's continuous efforts in providing targeted cancer therapies.